Table 1.
Patient characteristics in the 1st line endocrine setting (n = 16)
| Variable | n (%), median (range) |
|---|---|
|
Median age at AI initiation |
55 years (39–72) |
|
Performance status |
|
| 0 |
4 (25%) |
| 1 |
10 (62.5%) |
| 2 |
1 (6.25%) |
| 3 |
1 (6.25%) |
|
Menopausal status |
|
| Premenopausal |
2 (12.5%) |
| Postmenopausal |
14 (87.5%) |
|
Median body mass index |
27.6 kg/m2 (20.3–52.7) |
|
Number of co-morbidities |
|
| 0–1 |
13 (81%) |
| 2–3 |
3 (19%) |
| 4–5 |
0 (0%) |
|
Stage at diagnosis |
|
| Non metastatic |
11 (69%) |
| Locally recurrent/ metastatic |
5 (31%) |
|
Sites of metastases at time of AI initiation |
|
| Lung |
12 (75%) |
| [Lung as only site of metastases] |
10 (62.5%) |
| Pelvis |
4 (25%) |
| Peritoneum |
3 (19%) |
|
Tumour volume at time of AI initiation |
|
| Low |
6 (37.5%) |
| High |
10 (62.5%) |
|
Number of metastases |
|
| Oligometastatic |
7 (44%) |
| Multiple | 9 (56%) |
AI, aromatase inhibitor.